| abstract |
The invention describes vaccines useful for the prevention of COVID-19, wherein recombinant antigens of non-glycosylated domains in the S-RBD region encoded in the SARS-CoV-2 virus genome of both the original Wuhan virus strain and the B.1.1.7 (UK) and B.1.351 (South African) virus strain variants were designed and expressed. The purified antigens of the invention were able to induce the production of polyclonal antibodies in animals, as well as a strong immune response, even by means of nasal and/or intranasal administration. Additionally, IgG antibodies that recognise said antigens were detected in sera from recovered COVID-19 patients. The invention highlights the usefulness of the antigens based on the non-N-glycosylated region of the RBD of SARS-CoV-2 for the development of monovalent and/or polyvalent vaccines effective against COVID-19, for the diagnosis of said illness, and for the prevention and immunotherapy thereof by means of the production and use of monovalent and/or polyvalent anti-COVID-19 hyperimmune plasmas and/or sera. |